The effect of Bumethanide treatment on seizure controlling in patients with drug resistance temporal lobe epilepsies candidate for surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012115368N1

Enrollment

Registered

2011-02-05

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporal Lobe Epilepsy. other epilepsy

Interventions

Bumetanide (1mg/day) orally for 3 months.

Treatment - Drugs

Bumetanide (1mg/day) orally for 3 months

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion: 1) Suffering from drug resistance temporal lobe epilepsy 2) Candidate for temporal lobectomy 3) Giving informed consent. Exclusion: Contraindication for Bumethanide

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Seizure occurrence. Timepoint: 1 month before and 1 month after intervention. Method of measurement: EEG.	—

Secondary

Measure	Time frame
Dose reduction of anti-epileptic drugs. Timepoint: 3 months before and 3 months after intervention. Method of measurement: dosage.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoudreza Hadjighassem

Cellular and Molecular Research Center

drhadjighassem@iums.ac.ir+98 21 8805 2984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026